Determining clinically meaningful decline in preclinical Alzheimer disease

In the first segment, Dr. Gregory Day talks with Dr. Philip Insel about his paper on determining clinically meaningful decline in preclinical Alzheimer disease. In the second part of the podcast, Dr. Sarah Tabrizi talks about targeting Huntington expression in patients with Huntington's disease in her interview with Dr. Jeffrey Ratliff. Read Dr. Tabrizi's paper in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa1900907?query=recirc_curatedRelated_article.